Biofrontera (BFRI) Competitors $0.93 -0.04 (-3.73%) Closing price 08/15/2025 03:49 PM EasternExtended Trading$0.92 -0.01 (-0.75%) As of 08/15/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. PLUR, STTK, SNYR, XLO, ENLV, SCYX, FGEN, AKTX, PEPG, and ALXOShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Pluri (PLUR), Shattuck Labs (STTK), Synergy CHC (SNYR), Xilio Therapeutics (XLO), Enlivex Therapeutics (ENLV), SCYNEXIS (SCYX), FibroGen (FGEN), Akari Therapeutics (AKTX), PepGen (PEPG), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Its Competitors Pluri Shattuck Labs Synergy CHC Xilio Therapeutics Enlivex Therapeutics SCYNEXIS FibroGen Akari Therapeutics PepGen ALX Oncology Biofrontera (NASDAQ:BFRI) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Is BFRI or PLUR more profitable? Biofrontera has a net margin of -42.34% compared to Pluri's net margin of -2,563.29%. Biofrontera's return on equity of -1,104.09% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-42.34% -1,104.09% -82.28% Pluri -2,563.29%-4,191.91%-85.40% Which has higher valuation & earnings, BFRI or PLUR? Biofrontera has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$37.32M0.25-$17.76M-$2.26-0.41Pluri$330K118.53-$20.89M-$5.53-0.90 Do institutionals and insiders hold more shares of BFRI or PLUR? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 25.9% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer BFRI or PLUR? In the previous week, Biofrontera had 10 more articles in the media than Pluri. MarketBeat recorded 12 mentions for Biofrontera and 2 mentions for Pluri. Pluri's average media sentiment score of 0.44 beat Biofrontera's score of 0.27 indicating that Pluri is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Neutral Pluri Neutral Do analysts rate BFRI or PLUR? Biofrontera presently has a consensus price target of $2.75, suggesting a potential upside of 195.70%. Pluri has a consensus price target of $12.00, suggesting a potential upside of 141.45%. Given Biofrontera's higher probable upside, research analysts plainly believe Biofrontera is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, BFRI or PLUR? Biofrontera has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. SummaryBiofrontera beats Pluri on 9 of the 14 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.43M$3.15B$5.74B$9.81BDividend YieldN/A2.21%3.91%4.13%P/E Ratio-0.4120.8931.1125.08Price / Sales0.25333.55456.27111.51Price / CashN/A42.6136.7858.67Price / Book-2.028.659.086.18Net Income-$17.76M-$54.65M$3.26B$265.11M7 Day Performance-1.74%6.56%7.36%4.22%1 Month Performance11.22%7.53%5.47%2.01%1 Year Performance-31.62%13.69%30.61%23.75% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera2.6788 of 5 stars$0.93-3.7%$2.75+195.7%-19.8%$9.43M$37.32M-0.4170News CoverageEarnings ReportPLURPluri2.252 of 5 stars$4.74+4.2%$12.00+153.2%-13.9%$35.81M$330K-0.86150Short Interest ↑STTKShattuck Labs3.5577 of 5 stars$0.76+3.2%$7.50+883.6%-69.6%$35.41M$5.72M-0.55100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpSNYRSynergy CHC4.392 of 5 stars$3.92+2.1%$10.00+155.1%N/A$35.29M$34.83M0.0040News CoverageEarnings ReportAnalyst RevisionXLOXilio Therapeutics2.7922 of 5 stars$0.70+2.9%$3.00+328.6%-14.6%$35.22M$6.34M-0.8370News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionENLVEnlivex Therapeutics3.3324 of 5 stars$1.57+6.8%$10.00+536.9%+49.2%$34.77MN/A-2.3870News CoverageShort Interest ↓Gap UpSCYXSCYNEXIS1.3899 of 5 stars$0.86-2.3%N/A-51.5%$34.34M$3.75M-1.5460News CoverageEarnings ReportFGENFibroGen4.601 of 5 stars$9.25+10.5%$43.00+364.9%+2.6%$33.83M$7.00M-24.34570Earnings ReportAnalyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeAKTXAkari Therapeutics3.1104 of 5 stars$1.02-2.9%$5.00+390.2%-68.4%$33.78MN/A0.009Positive NewsUpcoming EarningsPEPGPepGen3.3542 of 5 stars$1.14+12.9%$7.67+572.5%-85.8%$33.13MN/A-0.3930Gap UpHigh Trading VolumeALXOALX Oncology2.906 of 5 stars$0.62+0.1%$3.30+436.5%-75.7%$32.81MN/A-0.2540Earnings ReportGap Down Related Companies and Tools Related Companies PLUR Competitors STTK Competitors SNYR Competitors XLO Competitors ENLV Competitors SCYX Competitors FGEN Competitors AKTX Competitors PEPG Competitors ALXO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access